JP2024099041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024099041A5 JP2024099041A5 JP2024073463A JP2024073463A JP2024099041A5 JP 2024099041 A5 JP2024099041 A5 JP 2024099041A5 JP 2024073463 A JP2024073463 A JP 2024073463A JP 2024073463 A JP2024073463 A JP 2024073463A JP 2024099041 A5 JP2024099041 A5 JP 2024099041A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- atom
- acceptable salt
- compound according
- pharmacologically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025203466A JP2026026166A (ja) | 2018-09-06 | 2025-11-26 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018167369 | 2018-09-06 | ||
| JP2018167369 | 2018-09-06 | ||
| PCT/JP2019/035198 WO2020050406A1 (ja) | 2018-09-06 | 2019-09-06 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
| JP2020541321A JP7254818B2 (ja) | 2018-09-06 | 2019-09-06 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
| JP2023050936A JP7483975B2 (ja) | 2018-09-06 | 2023-03-28 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023050936A Division JP7483975B2 (ja) | 2018-09-06 | 2023-03-28 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203466A Division JP2026026166A (ja) | 2018-09-06 | 2025-11-26 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024099041A JP2024099041A (ja) | 2024-07-24 |
| JP2024099041A5 true JP2024099041A5 (https=) | 2025-01-14 |
Family
ID=69722459
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541321A Active JP7254818B2 (ja) | 2018-09-06 | 2019-09-06 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
| JP2023050936A Active JP7483975B2 (ja) | 2018-09-06 | 2023-03-28 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
| JP2024073463A Ceased JP2024099041A (ja) | 2018-09-06 | 2024-04-30 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
| JP2025203466A Pending JP2026026166A (ja) | 2018-09-06 | 2025-11-26 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541321A Active JP7254818B2 (ja) | 2018-09-06 | 2019-09-06 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
| JP2023050936A Active JP7483975B2 (ja) | 2018-09-06 | 2023-03-28 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203466A Pending JP2026026166A (ja) | 2018-09-06 | 2025-11-26 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US12370263B2 (https=) |
| EP (2) | EP3848054B1 (https=) |
| JP (4) | JP7254818B2 (https=) |
| KR (4) | KR102567590B1 (https=) |
| CN (3) | CN118878620A (https=) |
| AU (2) | AU2019337051B2 (https=) |
| BR (1) | BR112021003472A2 (https=) |
| CA (1) | CA3251690A1 (https=) |
| CO (1) | CO2021004032A2 (https=) |
| DK (1) | DK3848054T3 (https=) |
| ES (1) | ES3017008T3 (https=) |
| FI (1) | FI3848054T3 (https=) |
| HR (1) | HRP20250345T1 (https=) |
| HU (1) | HUE071437T2 (https=) |
| IL (2) | IL281247B2 (https=) |
| LT (1) | LT3848054T (https=) |
| MX (1) | MX2021002107A (https=) |
| PH (1) | PH12021550442A1 (https=) |
| PL (1) | PL3848054T3 (https=) |
| PT (1) | PT3848054T (https=) |
| RS (1) | RS66662B1 (https=) |
| SG (1) | SG11202101526YA (https=) |
| SI (1) | SI3848054T1 (https=) |
| SM (1) | SMT202500141T1 (https=) |
| TW (3) | TWI905974B (https=) |
| WO (1) | WO2020050406A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3848054B1 (en) | 2018-09-06 | 2025-01-29 | Daiichi Sankyo Company, Limited | Antibody-drug conjugates of cyclic dinucleotide derivatives |
| IL296124A (en) * | 2020-03-06 | 2022-11-01 | Daiichi Sankyo Co Ltd | Antibody-drug conjugate including novel cyclic dinucleotide derivative |
| TW202200136A (zh) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 癌治療方法 |
| WO2022050300A1 (ja) | 2020-09-02 | 2022-03-10 | 第一三共株式会社 | 新規エンド－β－Ｎ－アセチルグルコサミニダーゼ |
| CN116867795A (zh) * | 2021-02-01 | 2023-10-10 | 第一三共株式会社 | 抗体－免疫刺激剂偶联物的新型制造方法 |
| TW202241454A (zh) * | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體－免疫賦活化劑共軛物之新穎製造方法 |
| US20240279364A1 (en) | 2021-03-12 | 2024-08-22 | Daiichi Sankyo Company, Limited | Glycan, and method for producing medicine containing glycan |
| EP4326314A4 (en) * | 2021-04-23 | 2025-12-17 | Univ Maryland | FC-GLYCAN REMODELING FOR SITE-SPECIFIC ANTIBODIES CONJUGATION AND APPLICATIONS THEREOF |
| CA3222082A1 (en) * | 2021-06-25 | 2022-12-29 | Gary Brandt | Bis-benzimidazole sting agonist immunoconjugates, and uses thereof |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| CN115703845A (zh) * | 2021-08-05 | 2023-02-17 | 中国科学院上海药物研究所 | 寡糖连接子与侧链亲水性片段组合的糖链定点抗体-药物偶联物，其制法及用途 |
| WO2023061405A1 (zh) * | 2021-10-12 | 2023-04-20 | 成都科岭源医药技术有限公司 | 一种高稳定性的靶向接头-药物偶联物 |
| CA3236388A1 (en) | 2021-10-29 | 2023-05-04 | Daiichi Sankyo Company, Limited | Novel oligosaccharide, manufacturing intermediate for novel oligosaccharide, and method for manufacturing these |
| IL312728A (en) | 2021-11-30 | 2024-07-01 | Daiichi Sankyo Co Ltd | Protease-cleavable masked antibodies |
| TW202342106A (zh) | 2022-02-09 | 2023-11-01 | 日商第一三共股份有限公司 | 環境應答性遮蔽抗體及其利用 |
| CN118804983A (zh) | 2022-03-02 | 2024-10-18 | 第一三共株式会社 | 含Fc分子的制造方法 |
| JP2025166269A (ja) * | 2022-07-29 | 2025-11-06 | 第一三共株式会社 | 抗腫瘍効果を有する抗体薬物複合体の新規製造方法 |
| KR20250054799A (ko) | 2022-08-29 | 2025-04-23 | 다이이찌 산쿄 가부시키가이샤 | 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트 |
| KR20250064682A (ko) | 2022-09-09 | 2025-05-09 | 다이이찌 산쿄 가부시키가이샤 | 신규 올리고당, 그 올리고당의 제조 중간체, 및 그것들의 제조 방법 |
| WO2024107827A1 (en) * | 2022-11-16 | 2024-05-23 | The Broad Institute, Inc. | Therapeutic exploitation of sting channel activity |
| WO2024118785A2 (en) | 2022-11-30 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Tlr7 agonists and antibody-drug-conjugates thereof |
| EP4737483A1 (en) | 2023-06-30 | 2026-05-06 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate production method including purification step using activated carbon material |
| TW202545568A (zh) * | 2024-01-29 | 2025-12-01 | 日商第一三共股份有限公司 | 抗her2抗體-藥物結合物與其他劑之組合 |
| WO2025183064A1 (ja) * | 2024-02-28 | 2025-09-04 | 第一三共株式会社 | 抗ｃｄｈ６抗体－薬物コンジュゲートと他剤との組み合わせ |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| IL161686A0 (en) | 2001-11-01 | 2004-09-27 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| WO2004008099A2 (en) | 2002-07-15 | 2004-01-22 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| JP5356648B2 (ja) | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス， インコーポレイテッド | 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用 |
| WO2007133855A2 (en) | 2006-03-27 | 2007-11-22 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| BRPI0816094A2 (pt) | 2007-08-30 | 2015-03-03 | Daiichi Sankyo Co Ltd | Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo. |
| US8809496B2 (en) | 2009-09-03 | 2014-08-19 | The Noguchi Institute | Production method of 11-sugar sialylglycopeptide |
| US9175326B2 (en) | 2011-03-03 | 2015-11-03 | University Of Maryland, Baltimore | Transglycosylation activity of glycosynthase mutants of an endo-beta-N-acetylglucosaminidase (endo-D) from streptococcus pneumoniae |
| US10851174B2 (en) | 2011-03-03 | 2020-12-01 | University Of Maryland, Baltimore | Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof |
| IN2014DN06806A (https=) | 2012-02-10 | 2015-05-22 | Univ Maryland | |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| US9695212B2 (en) | 2012-12-13 | 2017-07-04 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| EP2934598B1 (en) | 2012-12-19 | 2018-04-18 | Board Of Regents, The University Of Texas System | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway |
| US9840533B2 (en) | 2013-04-29 | 2017-12-12 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| WO2014189806A1 (en) | 2013-05-18 | 2014-11-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| US20160235861A1 (en) | 2013-10-14 | 2016-08-18 | SynAffix. B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
| US9987373B2 (en) | 2013-10-14 | 2018-06-05 | Synaffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
| WO2015057063A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
| WO2015057066A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
| WO2015074145A1 (en) | 2013-11-22 | 2015-05-28 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
| CR20160564A (es) | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| DE102014214408A1 (de) | 2014-07-23 | 2016-01-28 | Wacker Chemie Ag | Härtbare Organopolysiloxanzusammensetzungen |
| EP4530348A3 (en) | 2014-12-15 | 2025-08-06 | Basf Se | Detergent composition comprising subtilase variants |
| US11559581B2 (en) | 2015-01-09 | 2023-01-24 | Oxford University Innovation Limited | Antibody conjugates and methods of making the antibody conjugates |
| EA035817B1 (ru) | 2015-03-10 | 2020-08-14 | Адуро Байотек, Инк. | Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона" |
| WO2016161372A1 (en) | 2015-04-01 | 2016-10-06 | President And Fellows Of Harvard College | Immunoconjugates for programming or reprogramming of cells |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| CN108026518B (zh) | 2015-07-16 | 2022-09-06 | 第一三共株式会社 | 新型endos突变型酶 |
| JP6895424B2 (ja) | 2015-08-12 | 2021-06-30 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂａｃｅ１阻害剤 |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| KR102222186B1 (ko) | 2015-08-13 | 2021-03-03 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
| JP2018534295A (ja) | 2015-10-28 | 2018-11-22 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法 |
| EP3368092B9 (en) * | 2015-10-29 | 2020-07-29 | Novartis AG | Antibody conjugates comprising toll-like receptor agonist |
| CN107849084B (zh) | 2015-12-03 | 2021-09-14 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为sting调节剂的环状嘌呤二核苷酸 |
| DE212016000029U1 (de) | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
| US20170158772A1 (en) | 2015-12-07 | 2017-06-08 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct - agonist conjugates and methods of use thereof |
| US10723756B2 (en) | 2016-01-11 | 2020-07-28 | Innate Tumor Immunity Inc. | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
| KR102789862B1 (ko) | 2016-01-11 | 2025-04-03 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드 |
| NZ746112A (en) | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| WO2017176664A1 (en) | 2016-04-07 | 2017-10-12 | Chevron U.S.A. Inc. | Smart gel sealants for well systems |
| JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| PT3440076T (pt) | 2016-04-07 | 2022-07-29 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas úteis como modeladores de proteína |
| US11486223B2 (en) | 2016-04-07 | 2022-11-01 | Chevron U.S.A. Inc. | Method for sealing a void in a well using smart gels |
| WO2018003983A1 (ja) | 2016-07-01 | 2018-01-04 | 第一三共株式会社 | ｈＡＮＰ－Ｆｃ含有分子コンジュゲート |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| IL264049B2 (en) | 2016-07-06 | 2023-11-01 | Sperovie Biosciences Inc | Compounds, preparations and methods for treating the disease |
| US20190345191A1 (en) | 2016-08-31 | 2019-11-14 | Innate Tumor Immunity, Inc. | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
| US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
| PT3523287T (pt) | 2016-10-04 | 2021-10-06 | Merck Sharp & Dohme | Compostos de benzo[b]tiofeno como agonistas de sting |
| KR20190066026A (ko) | 2016-10-07 | 2019-06-12 | 다이이찌 산쿄 가부시키가이샤 | 항 her2 항체-약물 콘주게이트 투여에 의한 내성암의 치료 |
| US11001605B2 (en) | 2016-10-07 | 2021-05-11 | Biolog Life Science Institute Gmbh & Co. Kg | Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways |
| JP2018090562A (ja) * | 2016-12-01 | 2018-06-14 | 武田薬品工業株式会社 | 環状ジヌクレオチド |
| PE20210255A1 (es) | 2016-12-01 | 2021-02-10 | Takeda Pharmaceuticals Co | Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon) |
| WO2018118665A1 (en) * | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| US20190336615A1 (en) | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| TW202532104A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| JP6967739B2 (ja) | 2017-11-14 | 2021-11-17 | パナソニックＩｐマネジメント株式会社 | 給湯機 |
| EP3848054B1 (en) | 2018-09-06 | 2025-01-29 | Daiichi Sankyo Company, Limited | Antibody-drug conjugates of cyclic dinucleotide derivatives |
-
2019
- 2019-09-06 EP EP19857433.7A patent/EP3848054B1/en active Active
- 2019-09-06 PT PT198574337T patent/PT3848054T/pt unknown
- 2019-09-06 US US17/273,666 patent/US12370263B2/en active Active
- 2019-09-06 MX MX2021002107A patent/MX2021002107A/es unknown
- 2019-09-06 RS RS20250327A patent/RS66662B1/sr unknown
- 2019-09-06 JP JP2020541321A patent/JP7254818B2/ja active Active
- 2019-09-06 FI FIEP19857433.7T patent/FI3848054T3/fi active
- 2019-09-06 BR BR112021003472-2A patent/BR112021003472A2/pt unknown
- 2019-09-06 WO PCT/JP2019/035198 patent/WO2020050406A1/ja not_active Ceased
- 2019-09-06 AU AU2019337051A patent/AU2019337051B2/en active Active
- 2019-09-06 TW TW113138233A patent/TWI905974B/zh active
- 2019-09-06 CN CN202410810879.XA patent/CN118878620A/zh active Pending
- 2019-09-06 TW TW108132368A patent/TWI825170B/zh active
- 2019-09-06 HU HUE19857433A patent/HUE071437T2/hu unknown
- 2019-09-06 IL IL281247A patent/IL281247B2/en unknown
- 2019-09-06 KR KR1020217009642A patent/KR102567590B1/ko active Active
- 2019-09-06 DK DK19857433.7T patent/DK3848054T3/da active
- 2019-09-06 ES ES19857433T patent/ES3017008T3/es active Active
- 2019-09-06 CA CA3251690A patent/CA3251690A1/en active Pending
- 2019-09-06 HR HRP20250345TT patent/HRP20250345T1/hr unknown
- 2019-09-06 KR KR1020237005621A patent/KR102567591B1/ko active Active
- 2019-09-06 TW TW112114344A patent/TWI861820B/zh active
- 2019-09-06 SG SG11202101526YA patent/SG11202101526YA/en unknown
- 2019-09-06 SM SM20250141T patent/SMT202500141T1/it unknown
- 2019-09-06 KR KR1020257016237A patent/KR20250078590A/ko active Pending
- 2019-09-06 KR KR1020237027378A patent/KR102810513B1/ko active Active
- 2019-09-06 CN CN201980058151.3A patent/CN112714649B/zh active Active
- 2019-09-06 SI SI201930902T patent/SI3848054T1/sl unknown
- 2019-09-06 CN CN202410810871.3A patent/CN118846110A/zh active Pending
- 2019-09-06 LT LTEPPCT/JP2019/035198T patent/LT3848054T/lt unknown
- 2019-09-06 IL IL315138A patent/IL315138A/en unknown
- 2019-09-06 PL PL19857433.7T patent/PL3848054T3/pl unknown
- 2019-09-06 EP EP25154566.1A patent/EP4524154A3/en active Pending
-
2021
- 2021-03-02 PH PH12021550442A patent/PH12021550442A1/en unknown
- 2021-03-30 CO CONC2021/0004032A patent/CO2021004032A2/es unknown
-
2023
- 2023-02-27 AU AU2023201159A patent/AU2023201159B2/en active Active
- 2023-03-28 JP JP2023050936A patent/JP7483975B2/ja active Active
-
2024
- 2024-04-22 US US18/642,667 patent/US20240293567A1/en active Pending
- 2024-04-30 JP JP2024073463A patent/JP2024099041A/ja not_active Ceased
-
2025
- 2025-11-26 JP JP2025203466A patent/JP2026026166A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024099041A5 (https=) | ||
| JP2023105175A (ja) | グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体 | |
| US20080293800A1 (en) | Cytotoxic Compounds and Conjugates | |
| CN103570792B (zh) | 蟾毒灵衍生物、其制备方法、药物组合物及用途 | |
| US20060247295A1 (en) | Cytotoxic compounds and conjugates with cleavable substrates | |
| JP2021523225A5 (https=) | ||
| US20060004081A1 (en) | Cytotoxic compounds and conjugates | |
| WO2018148650A1 (en) | Trigger-activatable sugar conjugates for cancer-selective labeling and targeting | |
| JP2022553702A5 (https=) | ||
| AU2017237186A1 (en) | Process for the preparation of PEGylated drug-linkers and intermediates thereof | |
| KR20080068084A (ko) | 씨씨-1065 유사체를 제조하기 위한 방법 및 화합물 | |
| JP2006511534A5 (https=) | ||
| TR201802539T4 (tr) | CC-1065 analoglarının ve bifonksiyonel bağlayıcıların konjugatları. | |
| JP2022516427A5 (https=) | ||
| JP2024532845A5 (https=) | ||
| CN111417408B (zh) | 药物接头化合物的制备方法 | |
| JP2026507549A (ja) | 改良された特性を有するテトラジン類 | |
| US20130005696A1 (en) | Bufadienolide derivatives, preparing process thereof, composition comprising the same and the use thereof | |
| JP5612467B2 (ja) | Ｆｍｏｃをベースとした加水分解性リンカーの調製方法 | |
| KR20180055135A (ko) | 벤조사이아졸 유도체가 결합된 리간드-금속 복합체 및 이의 제조 방법 | |
| JP2022545181A5 (https=) | ||
| JP2002533418A (ja) | アントラキノン抗癌剤 | |
| US20250161506A1 (en) | Antibody Drug Conjugate Based on Metal N-Heterocyclic Carbene Complex, a Method of Preparing the Same and the Use of the Same in Anticancer Treatment | |
| JP4590198B2 (ja) | 葉酸誘導体の製造方法 | |
| KR20170041562A (ko) | 벤조셀레노펜계 화합물 및 이를 포함하는 항체-약물 결합체 |